View Post

The Pain Clinic – Solving the five most common problems in clinical trials

In Clinical Trials by Barbara Jacoby

At Partnerships in Clinical Trials in Barcelona (Nov 2018), Kate O’Brien, formally a senior research nurse and now a site consultant, led a problem solving forum for all aspects of running clinical trials. Here she examines the most common problems and the potential solutions to them. The concept behind this initiative was to identify some of the issues that face different areas of …

View Post

Translating Patient Feedback Into Better Cancer Treatments

In Clinical Trials by Barbara Jacoby

From: Cedars-Sinai A major new study now underway aims to better incorporate patient feedback into clinical trials that help determine which new cancer treatments will be approved for use. The project, supported by a five-year, $3.4 million grant from the National Cancer Institute, involves statisticians, clinicians and patient advocates. The team is analyzing data from previous and ongoing clinical trials …

View Post

Israeli treatment freezes cancerous tumors, eliminating need for surgery

In Clinical Trials by Barbara Jacoby

By: WKRC From: local12.com CAESAREA, Israel (CBS Newspath/Reuters) – When Nelida Ivaldi was diagnosed with a tumor in her breast, she was terrified of what she thought was going to be a long, painful treatment. But after undergoing cryoablation therapy to freeze her tumor, she was surprised by how quick and painless the whole thing was. Ivaldi, a retired teacher, …

View Post

Mayo Clinic sees 80% increase in breast cancer clinical trial enrollment with IBM Watson’s clinical trial matching system

In Clinical Trials by Barbara Jacoby

By: Julie Spitzer  From: beckershospitalreview.com Rochester, Minn-based Mayo Clinic enrolled more patients in its breast cancer clinical trials after implementing IBM Watson Health’s Watson for Clinical Trials Matching, a cognitive computing system, according to early results of use in Mayo’s oncology practice. Although clinical trials increase patients’ access to new, promising or emerging treatments, matching and enrolling them in trials …

View Post

New study suggests loosening strict comorbidity criteria would open trials to thousands of previously exempt patients

In Clinical Trials by Barbara Jacoby

By: Diane Mapes From: fredhutch.org How do you make cancer clinical trials available to more patients? A new study published today in JAMA Oncology and led by Dr. Joseph Unger at Fred Hutchinson Cancer Research Center offers a tantalizing solution: loosen up the strict eligibility criteria. Low clinical trial participation is a problem that’s plagued cancer researchers for decades, with …

View Post

UIC drug crosses blood-brain barrier, now in clinical trials for cancer patients

In Clinical Trials by Barbara Jacoby

From: today.uic.edu A drug invented at the University of Illinois at Chicago is now being studied in humans as a treatment for difficult-to-treat and chemoresistant cancers including glioblastoma, or GBM, the deadliest type of brain tumor. UIC professor Irina Gaisina, one of the inventors of the drug, has been closely involved in its research and development, which began more than …

View Post

Marker Therapeutics Provides Updates of its Lead Clinical Programs

In Clinical Trials by Barbara Jacoby

Source: Marker Therapeutics, Inc. From: prnewswire.com Reports clinical data updates with MultiTAA T cells in lymphoma, multiple myeloma and acute lymphoblastic leukemia Reports completion of enrollment for TPIV200 Phase II study in ovarian cancer Reports interim immunogenicity findings of TPIV200 Phase II study in triple negative breast cancer Marker Therapeutics, Inc. (NASDAQ: MRKR), a clinical-stage immuno-oncology company specializing in the development …

View Post

First-in-human Study of Precision Immune Stimulant PIN-2 Demonstrated Pharmacologic Activity and Safety in Patients with Advanced Solid Tumors

In Clinical Trials by Barbara Jacoby

Source: PIN Pharma, Inc. From: argus-press.com PIN Pharma, Inc., today announced final results of a first-in-human clinical trial of its novel immunomodulating agent PIN-2 in subjects with advanced solid tumors. This was an open-label, repeat-dose study with a primary objective to assess the pharmacodynamic activity of PIN-2. Pharmacodynamic biomarkers that signal changes in the human immune system were used to …

View Post

FDA Grants Priority Review Designation for Heron Therapeutics’ NDA for HTX-011, a Non-Opioid for Postoperative Pain Management

In Clinical Trials by Barbara Jacoby

Source: Heron Therapeutics, Inc. From: prnewswire.com Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that the U.S. Food and Drug Administration (FDA) has accepted the new drug application (NDA) for Heron’s investigational agent, HTX-011, and has …

View Post

JHL Biotech Announces First Patient Randomized in the Phase III Study of JHL1101 to Treat Diffuse Large B-Cell Lymphoma

In Clinical Trials by Barbara Jacoby

Source: JHL Biotech From: prnewswire.co.uk JHL Biotech announced today that the first patient at Beijing Cancer Hospital has been successfully randomized in the Phase III study of JHL1101 to treat diffuse large B-cell lymphoma (DLBCL). The Phase III study is a multinational, randomized, double-blind, positive-controlled, parallel group clinical study.  It compares the efficacy and safety of JHL1101 in combination with CHOP …